Cargando…

Moderately Hypofractionated Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost for Prostate Cancer: Five-Year Toxicity Results From a Prospective Phase I/II Trial

BACKGROUND: In this phase I/II trial, 5-year physician-assessed toxicity and patient reported quality of life data is reported for patients undergoing moderately hypofractionated intensity modulated radiation therapy (IMRT) for prostate cancer using a simultaneous integrated boost (SIB) and pelvic l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ricco, Anthony, Mukhopadhyay, Nitai, Deng, Xiaoyan, Holdford, Diane, Skinner, Vicki, Saraiya, Siddharth, Moghanaki, Drew, Anscher, Mitchell S., Chang, Michael G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471868/ https://www.ncbi.nlm.nih.gov/pubmed/32974208 http://dx.doi.org/10.3389/fonc.2020.01686

Ejemplares similares

Moderately Hypofractionated Radiotherapy with Simultaneous Integrated Boost in Prostate Cancer: A Comparative Study with Conventionally Fractionated Radiation
por: Cante, Domenico, et al.
Publicado: (2020)

Accelerated hypofractionated breast radiotherapy with simultaneous integrated boost: a feasibility study
por: Yadav, Budhi Singh, et al.
Publicado: (2022)

Acute and Late Toxicity after Moderate Hypofractionation with Simultaneous Integrated Boost (SIB) Radiation Therapy for Prostate Cancer. A Single Institution, Prospective Study
por: Jorgo, Kliton, et al.
Publicado: (2019)

Acute skin toxicity of ultra-hypofractionated whole breast radiotherapy with simultaneous integrated boost for early breast cancer
por: Montero, Angel, et al.
Publicado: (2023)

Feasibility of a simultaneously integrated boost concept for hypofractionated stereotactic radiotherapy of unresected brain metastases
por: Kornhuber, Christine, et al.
Publicado: (2023)

Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience
por: Zhong, Liangzhi, et al.
Publicado: (2019)

Ten Year Results of Extensive Nodal Radiotherapy and Moderately Hypofractionated Simultaneous Integrated Boost in Unfavorable Intermediate-, High-, and Very High-Risk Prostate Cancer
por: Di Muzio, Nadia Gisella, et al.
Publicado: (2021)

A Hypofractionated Radiotherapy Schedule with a Simultaneous Integrated Boost for Breast Cancer: Outcomes including Late Toxicity and Health Quality
por: Akgun, Zuleyha, et al.
Publicado: (2023)

Moderate hypofractionation for prostate cancer
por: Arcangeli, Stefano, et al.
Publicado: (2017)

Moderate hypofractionation for prostate cancer
por: Lee, W. Robert, et al.
Publicado: (2018)

Feasibility and Outcomes of Hypofractionated Simultaneous Integrated Boost-Intensity Modulated Radiotherapy for Malignant Gliomas: A Preliminary Report
por: Cha, Jihye, et al.
Publicado: (2014)

Adjuvant hypofractionated radiotherapy with simultaneous integrated boost after breast-conserving surgery: results of a prospective trial
por: Krug, David, et al.
Publicado: (2020)

Adjuvant hypofractionated radiotherapy with simultaneous integrated boost after breast-conserving surgery: A systematic literature review
por: Schmitt, Martin, et al.
Publicado: (2022)

Single-Institution Prospective Evaluation of Moderately Hypofractionated Whole-Breast Radiation Therapy With Simultaneous Integrated Boost With or Without Lymphatic Drainage Irradiation After Breast-Conserving Surgery
por: Unterkirhere, Olga, et al.
Publicado: (2023)

Comparison of four-year toxicities and local control of ultra-hypofractionated vs moderate-hypofractionated image guided prostate radiation with HDR brachytherapy boost: A phase I-II single institution trial
por: Beaudry, M.M., et al.
Publicado: (2023)

Hypofractionated Image-Guided Radiation Therapy With Simultaneous-Integrated Boost Technique for Limited Metastases: A Multi-Institutional Analysis
por: Jacobs, Corbin D., et al.
Publicado: (2019)

Poor-Prognosis Patients Affected by Glioblastoma: Retrospective Study of Hypofractionated Radiotherapy with Simultaneous Integrated Boost and Concurrent/Adjuvant Temozolomide
por: Gregucci, Fabiana, et al.
Publicado: (2021)

Dose-escalation by hypofractionated simultaneous integrated boost IMRT in unresectable stage III non-small-cell lung cancer
por: Zhang, Qin, et al.
Publicado: (2022)

Hypofractionation with simultaneous integrated boost after breast-conserving surgery: Long term results of two phase-II trials
por: Pfaffendorf, Charlotte, et al.
Publicado: (2022)

Long-Term Results of Postoperative Hypofractionated Accelerated Breast and Lymph Node Radiotherapy (HypoAR) with Hypofractionated Boost
por: Koukourakis, Ioannis M., et al.
Publicado: (2021)

Simultaneous integrated boost (SIB) to dominant intra-prostatic lesions during extreme hypofractionation for prostate cancer: the impact of rectal spacers
por: Osman, Sarah O. S., et al.
Publicado: (2022)

Use of Nab-Paclitaxel Plus Gemcitabine Followed by Hypofractionated Tomotherapy With Simultaneous Integrated Boost in Patients With Locally Advanced Pancreatic Cancer
por: Shi, Zhan, et al.
Publicado: (2022)

Hypofractionated whole breast irradiation with simultaneous integrated boost in breast cancer using helical tomotherapy with or without regional nodal irradiation: A report of acute toxicities
por: Chitapanarux, Imjai, et al.
Publicado: (2023)

Moderate hypofractionated radiotherapy after prostatectomy for cancer patients: toxicity and clinical outcome
por: Barra, Salvina, et al.
Publicado: (2018)

Toxicity and Outcomes of Moderately Hypofractionated Radiation for Prostate Cancer With Seminal Vesicle Involvement
por: Acklin-Wehnert, Scarlett, et al.
Publicado: (2023)

A comparative study on hypofractionated whole-breast irradiation with sequential or simultaneous integrated boost on different positions after breast-conserving surgery
por: Yu, Ting, et al.
Publicado: (2021)

Long-term outcome and toxicity of hypofractionated stereotactic body radiotherapy as a boost treatment for head and neck cancer: the importance of boost volume assessment
por: Lee, Dong Soo, et al.
Publicado: (2012)

Dosimetric and Radiobiological Comparison of Five Techniques for Postmastectomy Radiotherapy with Simultaneous Integrated Boost
por: Tang, Du, et al.
Publicado: (2020)

Long-term oncological outcomes of hypofractionated versus conventional fractionated whole breast irradiation with simultaneous integrated boost in early-stage breast cancer
por: Lertbutsayanukul, Chawalit, et al.
Publicado: (2022)

Patient Survival With and Without Radiation Therapy for Early-Stage Diffuse Large B-Cell Lymphoma in the Era of PET and Rituximab
por: McLaughlin, Christopher, et al.
Publicado: (2022)

Outcomes and toxicity from a prospective study of moderately hypofractionated radiation therapy for prostate cancer
por: Wang, Wei Gang, et al.
Publicado: (2017)

Moderately hypofractionated radiotherapy for localized prostate cancer: updated long-term outcome and toxicity analysis
por: Tamihardja, Jörg, et al.
Publicado: (2020)

Normofractionated and moderately hypofractionated proton therapy: comparison of acute toxicity and early quality of life outcomes
por: Pelak, Maciej J., et al.
Publicado: (2022)

Hypofractionated Simultaneous Integrated Boost Radiotherapy Versus Conventional Fractionation Radiotherapy of Early Breast Cancer After Breast-Conserving Surgery: Clinical Observation and Analysis
por: Dong, Jinling, et al.
Publicado: (2021)

Dosimetric feasibility of moderately hypofractionated/dose escalated radiation therapy for localised prostate cancer with intensity-modulated proton beam therapy using simultaneous integrated boost (SIB-IMPT) and impact of hydrogel prostate-rectum spacer
por: Ahmad Khalil, Dalia, et al.
Publicado: (2022)

Hypofractionated Proton Boost Combined with External Beam Radiotherapy for Treatment of Localized Prostate Cancer
por: Johansson, Silvia, et al.
Publicado: (2012)

Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer
por: Anwar, Mekhail, et al.
Publicado: (2016)

Long-term results of a phase II study of hypofractionated proton therapy for prostate cancer: moderate versus extreme hypofractionation
por: Ha, Boram, et al.
Publicado: (2019)

Targeting the TGF-β1 Pathway to Prevent Normal Tissue Injury After Cancer Therapy
por: Anscher, Mitchell S.
Publicado: (2010)

Post-Operative Accelerated-Hypofractionated Chemoradiation With Volumetric Modulated Arc Therapy and Simultaneous Integrated Boost in Glioblastoma: A Phase I Study (ISIDE-BT-2)
por: Ferro, Marica, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4tj6uq41n8rttodkqcpnpdfr1c